TY - JOUR A1 - Paulßen, Elisabeth A1 - Ngyugen, Hung Huy A1 - Kahlcke, Nils A1 - Deflon, Victor M. A1 - Abram, Ulrich T1 - Tricarbonyltechnetium(I) and -rhenium(I) complexes with N′-thiocarbamoylpicolylbenzamidines JF - Polyhedron N2 - N,N-Dialkylamino(thiocarbonyl)-N′-picolylbenzamidines react with (NEt4)2[M(CO)3X3] (M = Re, X = Br; M = Tc, X = Cl) under formation of neutral [M(CO)3L] complexes in high yields. The monoanionic NNS ligands bind in a facial coordination mode and can readily be modified at the (CS)NR1R2 moiety. The complexes [99Tc(CO)3(LPyMor)] and [Re(CO)3(L)] (L = LPyMor, LPyEt) were characterized by X-ray diffraction. Reactions of [99mTc(CO)3(H2O)3]+ with the N′-thiocarbamoylpicolylbenzamidines give the corresponding 99mTc complexes. The ester group in HLPyCOOEt allows linkage between biomolecules and the metal core. Y1 - 2012 U6 - http://dx.doi.org/10.1016/j.poly.2012.04.008 SN - 0277-5387 VL - 40 IS - 1 SP - 153 EP - 158 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Immel, Timo A1 - Grützke, Martin A1 - Späte, Anne-Katrin A1 - Groth, Ulrich A1 - Öhlschläger, Peter A1 - Huhn, Thomas T1 - Synthesis and X-ray structure analysis of a heptacoordinate titanium(IV)-bis-chelate with enhanced in vivo antitumor efficacy JF - Chemical Communications N2 - Chelate stabilization of a titanium(IV)–salan alkoxide by ligand exchange with 2,6-pyridinedicarboxylic acid (dipic) resulted in heptacoordinate complex 3 which is not redox-active, stable on silica gel and has increased aqueous stability. 3 is highly toxic in HeLa S3 and Hep G2 and has enhanced antitumor efficacy in a mouse cervical-cancer model. Y1 - 2012 U6 - http://dx.doi.org/10.1039/C2CC31624B SN - 1364-548X VL - 48 IS - 46 SP - 5790 EP - 5792 PB - Royal Society of Chemistry CY - Cambridge ER - TY - PAT A1 - Siegert, Petra A1 - Merkel, Marion A1 - Hellmuth, Hendrik A1 - O'Connell, Timothy A1 - Maurer, Karl-Heinz T1 - Stabilisierte flüssige enzymhaltige Tensidzubereitung (Einsatz einer das hydrolytische Enzym stabilisierenden Komponente, die eine Phenylalkyldicarbonsäure umfasst) [Offenlegungsschrift] T1 - Stabilized liquid tenside preparation comprising enzymes (using a component that stabilizes the hydrolytic enzyme and includes a phenylalkyldicarboxylic acid) [Europäische Patentanmeldung / Internationale Patentanmeldung] Y1 - 2012 SP - 1 EP - 15 PB - Deutsches Patent- und Markenamt / Europäisches Patentamt / WIPO CY - München / Den Hague / Genf ER - TY - PAT A1 - Siegert, Petra A1 - Merkel, Marion A1 - Hellmuth, Hendrik A1 - O'Connell, Timothy A1 - Maurer, Karl-Heinz T1 - Stabilisierte flüssige enzymhaltige Tensidzubereitung (Einsatz einer das hydrolytische Enzym stabilisierende Komponente, die eine Phthaloylglutaminsäure und/oder eine Phthaloylasparaginsäure umfasst) [Offenlegungsschrift] T1 - Stabilized liquid tenside preparation comprising enzymes (a component comprising a phthaloyl glutamine acid and/or a phthaloyl asparagine acid is used for stablizing the hydrolytic enzyme) [Europäische Patentanmeldung / Internationale Patentanmeldung] Y1 - 2012 SP - 1 EP - 16 PB - Deutsches Patent- und Markenamt / Europäisches Patentamt / WIPO CY - München / Den Hague / Genf ER - TY - PAT A1 - Siegert, Petra A1 - Merkel, Marion A1 - Hellmuth, Hendrik A1 - O'Connell, Timothy A1 - Maurer, Karl-Heinz T1 - Stabilisierte flüssige enzymhaltige Tensidzubereitung (Einsatz einer das hydrolytische Enzym stabilisierende Komponente, die eine Oligoamino-biphenyl-oligocarbonsäure umfasst) [Offenlegungsschrift] T1 - Stabilized liquid tenside preparation comprising enzymes (a component comprising an oligoamino-biphenyl-oligocarboxylic acid is used for stabilizing the hydrolytic enzyme) [Europäische Patentanmeldung / Internationale Patentanmeldung] Y1 - 2012 SP - 1 EP - 16 PB - Deutsches Patent- und Markenamt / Europäisches Patentamt / WIPO CY - München / Den Hague / Genf ER - TY - PAT A1 - Siegert, Petra A1 - Merkel, Marion A1 - Hellmuth, Hendrik A1 - O'Connell, Timothy A1 - Maurer, Karl-Heinz T1 - Stabilisierte flüssige enzymhaltige Tensidzubereitung (Einsatz einer das hydrolytische Enzym stabilisierende Komponente, die eine Aminophthalsäure umfasst) [Offenlegungsschrift] T1 - Stabilized liquid tenside preparation comprising enzymes (a component comprising an aminophthalic acid is used for stabilizing the hydrolytic enzyme) [Europäische Patentanmeldung / Internationale Patentanmeldung] Y1 - 2012 SP - 1 EP - 16 PB - Deutsches Patent- und Markenamt / Europäisches Patentamt / WIPO CY - München / Den Hague / Genf ER - TY - PAT A1 - Siegert, Petra A1 - Merkel, Marion A1 - Hellmuth, Hendrik A1 - O'Connell, Timothy A1 - Maurer, Karl-Heinz T1 - Stabilisierte flüssige enzymhaltige Tensidzubereitung (Einsatz einer das hydrolytische Enzym stabilisierende Komponente, die ein Monosaccharidglycerat umfasst) [Offenlegungsschrift] T1 - Stabilized liquid enzyme-containing surfactant preparation (using a component which comprises a monosaccharide glycerate and which stabilizes the hydrolytic enzyme) [Europäische Patentanmeldung / Internationale Patentanmeldung] Y1 - 2012 SP - 1 EP - 17 PB - Deutsches Patent- und Markenamt / Europäisches Patentamt / WIPO CY - München / Den Hague / Genf ER - TY - PAT A1 - Siegert, Petra A1 - Merkel, Marion A1 - Hellmuth, Hendrik A1 - O'Connell, Timothy A1 - Maurer, Karl-Heinz T1 - Stabilisierte flüssige enzymhaltige Tensidzubereitung (durch den Einsatz einer das hydrolytische Enzym stabilisierende Komponente, die eine mehrfach substituierte Benzolcarbonsäure umfasst, die an mindestens zwei Kohlenstoffatomen des Benzolrestes eine Carboxylgruppe aufweist) [Offenlegungsschrift] T1 - Stabilized liquid tenside preparation comprising enzymes (a component comprising a multiply substituted benzyl carboxylic acid comprising a carboxyl group on at least two carbon atoms of the benzyl radical is used for stabilizing the hydrolytic enzyme) [Europäische Patentanmeldung / Internationale Patentanmeldung] Y1 - 2012 SP - 1 EP - 16 PB - Deutsches Patent- und Markenamt / Europäisches Patentamt / WIPO CY - München / Den Hague / Genf ER - TY - CHAP A1 - Feuerriegel, Uwe A1 - Wittenhorst, Simon A1 - Hoffmann, Ulrich A1 - Pook, Michael T1 - Simulation von Wärmeübertragungsprozessen T2 - Tagungsband zur AALE-Tagung 2012 : 9. Fachkonferenz Y1 - 2012 SN - 978-3-8356-3305-6 N1 - AALE 2012 SP - 127 EP - 136 PB - Oldenbourg Industrieverlag CY - München ER - TY - JOUR A1 - Henken, F. E. A1 - Oosterhuis, K. A1 - Öhlschläger, Peter A1 - Bosch, L. A1 - Hooijberg, E. A1 - Haanen, J. B. A. G. A1 - Steenbergen, R. D. M. T1 - Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7 JF - Vaccine N2 - Persistent infection with high-risk human papillomaviruses (hrHPV) can result in the formation of anogenital cancers. As hrHPV proteins E6 and E7 are required for cancer initiation and maintenance, they are ideal targets for immunotherapeutic interventions. Previously, we have described the development of DNA vaccines for the induction of HPV16 E6 and E7 specific T cell immunity. These vaccines consist of ‘gene-shuffled’ (SH) versions of HPV16 E6 and E7 that were fused to Tetanus Toxin Fragment C domain 1 (TTFC) and were named TTFC-E6SH and TTFC-E7SH. Gene-shuffling was performed to avoid the risk of inducing malignant transformation at the vaccination site. Here, we describe the preclinical safety evaluation of these candidate vaccines by analysis of their transforming capacity in vitro using established murine fibroblasts (NIH 3T3 cells) and primary human foreskin keratinocytes (HFKs). We demonstrate that neither ectopic expression of TTFC-E6SH and TTFC-E7SH alone or in combination enabled NIH 3T3 cells to form colonies in soft agar. In contrast, expression of HPV16 E6WT and E7WT alone or in combination resulted in effective transformation. Similarly, retroviral transduction of HFKs from three independent donors with both TTFC-E6SH and TTFC-E7SH alone or in combination did not show any signs of immortalization. In contrast, the combined expression of E6WT and E7WT induced immortalization in HFKs from all donors. Based on these results we consider it justified to proceed to clinical evaluation of DNA vaccines encoding TTFC-E6SH and TTFC-E7SH in patients with HPV16 associated (pre)malignancies. Y1 - 2012 U6 - http://dx.doi.org/10.1016/j.vaccine.2012.04.013 SN - 0264-410X VL - 30 IS - 28 SP - 4259 EP - 4266 PB - Elsevier CY - Amsterdam ER -